000963:SSEHuadong Medicine Co., Ltd Analysis

Huadong Medicine trades at CNY 34.98, sitting below its 20‑day SMA of 35.73, 50‑day SMA of 37.70 and 200‑day SMA of 41.04, signaling a short‑term bearish bias. The MACD is in a bearish configuration and RSI sits at 39.2, suggesting modest oversold pressure, while the stock hovers just above a support zone around 33.30 and faces resistance near 37.32. Despite this technical backdrop, the beta of 0.03 and a 30‑day volatility of 22.6% indicate limited price swing risk and a relatively defensive profile.
Fundamentally, the company appears undervalued: its trailing PE of 16.6 is well below the industry average of 25.1, and a forward PE of 13.9 suggests earnings acceleration. Margins are solid (gross 33.9%, operating 11.6%), ROE stands at 15.6%, and the balance sheet is strong with a debt‑to‑equity of only 9.3% and ample cash generation (free cash flow > CNY 0.44 bn). The dividend yield of 2.66% with a payout ratio under 45% appears sustainable, and analysts’ consensus rates the stock as a “buy” with a target median price near CNY 50, implying upside of over 40%.